ATHA Athira Pharma Inc.

23.3
+0.03  (+0%)
Previous Close 23.27
Open 23.5
52 Week Low 15.79
52 Week High 29.7099
Market Cap $756,904,787
Shares 32,485,184
Float 28,705,148
Enterprise Value $535,503,009
Volume 98,871
Av. Daily Volume 337,300
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
P300
Alzheimer’s disease
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
ATH-1017 (LIFT-AD)
Alzheimer’s disease
Phase 2/3
Phase 2/3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
ATH-1017
Parkinson’s disease dementia
Phase 2
Phase 2
Phase 2 trial to be initiated by end of 2021.

Latest News

  1.  - LIFT-AD clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer's disease, actively enrolling 

     - Strong cash, cash equivalents and investments balance of $259.9 million as of September 30, 2020

    SEATTLE, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today reported financial results for the third quarter ended September 30, 2020 and provided recent business highlights.

    "At Athira, we are continuing to execute on our mission to restore neuronal health for those suffering from neurological diseases, including Alzheimer's…

     - LIFT-AD clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer's disease, actively enrolling 



     - Strong cash, cash equivalents and investments balance of $259.9 million as of September 30, 2020

    SEATTLE, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today reported financial results for the third quarter ended September 30, 2020 and provided recent business highlights.

    "At Athira, we are continuing to execute on our mission to restore neuronal health for those suffering from neurological diseases, including Alzheimer's, and we have successfully begun enrollment in our Phase 2/3 clinical study, LIFT-AD, evaluating our lead product candidate ATH-1017 in individuals with mild-to-moderate Alzheimer's disease," said Leen Kawas, Ph.D., President and Chief Executive Officer at Athira. "Supported by a strong cash position from our Series B financing in June and our initial public offering in September, we remain focused on advancing the development of ATH-1017 and our other pipeline programs."

    Recent Business Highlights and Updates

    Pipeline

    • Initiated patient dosing for the LIFT-AD study. In September 2020, Athira initiated patient dosing in a randomized, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating the safety, efficacy and tolerability of two dose levels of ATH-1017 in individuals with mild-to-moderate Alzheimer's disease. Clinical efficacy will be measured by improvement in cognition and global/functional assessments comparing treatment arms to placebo. Up to approximately 300 patients will be randomized across two dose groups and one placebo group on a 1:1:1 basis to receive a daily subcutaneous injection of ATH-1017 or placebo over a treatment course of 26 weeks.

    Corporate

    • Completed initial public offering (IPO). In September 2020, Athira Pharma completed its IPO of 12,000,000 shares of common stock at a public offering price of $17.00 per share, generating gross proceeds of $204.0 million before deducting underwriting discounts and commissions and estimated offering expenses. In October 2020, Athira sold an additional 1,397,712 shares of common stock to the underwriters of the IPO upon partial exercise of the underwriters' option to purchase additional shares at the initial public offering price, resulting in gross proceeds of approximately $23.8 million before deducting underwriting discounts and commissions and estimated offering expenses.

    Third Quarter 2020 Financial Results

    • Liquidity Position. Cash, cash equivalents and investments were $259.9 million as of September 30, 2020, as compared to $85.2 million as of June 30, 2020.
    • Research and Development (R&D) Expenses. R&D expenses were $5.8 million for the quarter ended September 30, 2020, as compared to $1.0 million for the same period in 2019. The increase was driven primarily by start-up activities by our clinical research organization and clinical drug supply manufacturers for Phase 2 Alzheimer's clinical trials of ATH-1017.
    • General and Administrative (G&A) Expenses. G&A expenses were $1.6 million for the quarter ended September 30, 2020, as compared to $0.5 million for the same period in 2019. The increase was primarily due to legal, accounting, technical and consulting services and personnel-related costs to support the increase in clinical activities.
    • Net Loss. Net loss was $8.5 million, or $1.12 loss per share, for the quarter ended September 30, 2020, as compared to $1.5 million or $0.43 loss per share, for the same period in 2019.

    About Athira Pharma, Inc.

    Athira, headquartered in Seattle, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer's and Parkinson's dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

    Forward-Looking Statements

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding ATH-1017 as a potential treatment for Alzheimer's and other dementias; Athira's platform technology and potential therapies; future development plans; clinical and regulatory objectives and the timing thereof; anticipated design of planned clinical trials; expectations regarding the potential efficacy and commercial potential of Athira's product candidates, including ATH-1017; the anticipated presentation of data; the results of Athira's research and development efforts and Athira's ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "pursue," and other similar expressions among others. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the preliminary data for Athira's ATH-1017 product candidate from the Phase 1a/b trials will not continue or persist; cessation or delay of any of the ongoing clinical trials and/or Athira's development of ATH-1017 may occur; future potential regulatory milestones of ATH-1017, including those related to current and planned clinical studies may be insufficient to support regulatory submissions or approval; the impact of the COVID-19 pandemic on Athira's business, research and clinical development plans and timelines and results of operations, including impact on our clinical trial sites and contractors who act for or on our behalf, may be more severe and more prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of Athira's product candidates; Athira's assumptions regarding its planned expenditures and sufficiency of its cash, cash equivalents and investments to fund operations may be incorrect; Athira's research and development efforts and its ability to advance product candidates into later stages of development may fail; any one or more of Athira's product candidates may not be successfully developed, approved or commercialized; adverse conditions in the general domestic and global economic markets; political and regulatory uncertainty following the results of the U.S. election in November 2020; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athira's clinical development plans as a result of the COVID-19 pandemic, which could further delay development timelines; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; impact of new or changing laws and regulations; as well as the other risks detailed in Athira's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

    "Athira," "Athira Pharma" and the Athira logo are registered trademarks or trademarks of Athira Pharma, Inc. in various jurisdictions. All other trademarks belong to their respective owner.

    Investor & Media Contact:

    Julie Rathbun

    Athira Pharma



    206-769-9219



    Athira Pharma, Inc.

    Condensed Consolidated Balance Sheets

    (Unaudited)

    (Amounts in thousands)

      September 30,  December 31, 
      2020  2019 
    Assets        
      Cash and cash equivalents  $165,725   $2,056 
      Short-term investments  60,547   0 
      Other short-term assets  5,994   104 
      Long-term investments  33,656   0 
      Other long-term assets  2,017   29 
    Total assets  $267,939   $2,189 
             
    Liabilities, Convertible preferred stock and stockholders' equity (deficit)        
      Current liabilities  $7,554   $1,273 
      Long-term liabilities  915   3,588 
    Total liabilities  8,469   4,861 
    Convertible preferred stock     17,051 
    Stockholders' equity (deficit)  259,470   (19,723)
    Total liabilities and stockholders' equity (deficit)  $267,939   $2,189 



    Athira Pharma, Inc.

    Condensed Consolidated Statements of Comprehensive Loss

    (Unaudited)

    (Amounts in thousands, except share and per share data)

      Three Months Ended September 30, 
      2020  2019 
    Operating expenses:        
    Research and development $5,830  $1,026 
    General and administrative  1,567   509 
    Total operating expenses  7,397   1,535 
    Loss from operations  (7,397)  (1,535)
    Other income (expense), net  (1,059)  5 
    Net loss $(8,456) $(1,530)
    Unrealized (loss)/gain on available-for-sale securities  7    
    Comprehensive loss attributable to common shareholders $(8,449) $(1,530)
    Net loss per share attributable to common stockholders,

       basic and diluted
     $(1.12) $(0.43)
    Weighted-average shares used in computing net loss per

       share attributable to common stockholders, basic

       and diluted
      7,564,538   3,554,345 

     

    Primary Logo

    View Full Article Hide Full Article
  2. SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Dr. Leen Kawas, President and Chief Executive Officer, and Dr. Hans Moebius, Chief Medical Officer, will participate in fireside chats at two upcoming investor conferences:

    • Stifel 2020 Virtual Healthcare Conference: Wednesday, November 18, 2020 at 2:40 pm ET
    • Jefferies Virtual London Healthcare Conference: Thursday, November 19, 2020 at 2:20 pm ET

    A live webcast of each presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations

    SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Dr. Leen Kawas, President and Chief Executive Officer, and Dr. Hans Moebius, Chief Medical Officer, will participate in fireside chats at two upcoming investor conferences:

    • Stifel 2020 Virtual Healthcare Conference: Wednesday, November 18, 2020 at 2:40 pm ET
    • Jefferies Virtual London Healthcare Conference: Thursday, November 19, 2020 at 2:20 pm ET

    A live webcast of each presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay of each webcast will also be available on the company website for 90 days following the presentations.

    About Athira Pharma, Inc.

    Athira, headquartered in Seattle, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer's and Parkinson's dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

    Investor & Media Contact:

    Julie Rathbun

    Athira Pharma



    206-769-9219

    Primary Logo

    View Full Article Hide Full Article
  3. - Expert neuropsychiatric clinician to discuss the testing method and its correlation to clinical results

    - Event to feature an in-clinic demonstration of P300 testing

    - Webcast to be held on Wednesday, Oct. 28, at 1 p.m. PT / 4 p.m. ET

    SEATTLE, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced it will host a webinar exploring the use of a common clinical measure, Event-Related Potential P300 latency (P300), as an assessment of working memory processing speed. The webinar will be webcast live on Wednesday, Oct. 28, at 1 p.m. PT / 4 p.m.ET and will feature:

    • A discussion…

    - Expert neuropsychiatric clinician to discuss the testing method and its correlation to clinical results

    - Event to feature an in-clinic demonstration of P300 testing

    - Webcast to be held on Wednesday, Oct. 28, at 1 p.m. PT / 4 p.m. ET

    SEATTLE, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced it will host a webinar exploring the use of a common clinical measure, Event-Related Potential P300 latency (P300), as an assessment of working memory processing speed. The webinar will be webcast live on Wednesday, Oct. 28, at 1 p.m. PT / 4 p.m.ET and will feature:

    • A discussion with Larry Ereshefsky, Pharm.D., BCPP, FCCP, a leader in the application of translational drug development tools for neurodegenerative and psychiatric disorders. Dr. Ereshefsky is Chief Scientific Officer at Apex Innovative Sciences and a member of Athira's Scientific Advisory Board.
    • Leen Kawas, Ph.D., President and Chief Executive Officer at Athira, who will review the company's completed and ongoing Phase 2/3 clinical trials of ATH-1017.

    Athira is measuring P300 in clinical trials of its investigational drug, ATH-1017, for treatment of mild-to-moderate Alzheimer's disease to establish a connection between this functional measurement and improved cognition.

    The live webcast event can be accessed from the investors' section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay will also be available on the company website for at least 30 days following the event.

    About Athira Pharma, Inc.

    Athira, headquartered in Seattle, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer's and Parkinson's dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

    Forward-Looking Statements

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "pursue," and other similar expressions among others. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks detailed in Athira's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

    Investor & Media Contact:

    Julie Rathbun

    Athira Pharma



    206-769-9219

    Primary Logo

    View Full Article Hide Full Article
  4. SEATTLE, Oct. 8, 2020 /PRNewswire/ -- Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the appointment of Mark Litton, PhD, MBA, Chief Operating Officer of Athira Pharma (NASDAQ:ATHA), to the company's Board of Directors.

    Dr. Litton is an experienced leader in the life sciences industry with a career spanning more than two decades of executive level leadership including as co-founder, Chief Business Officer, and Treasurer of Alder BioPharmaceuticals.

    "Mark's extensive expertise in the strategic growth, financing, and development of life science companies will be invaluable to Lumen Bio as we continue to develop Lumen's board and management expertise for the next phase of commercial development," said Brian Finrow, Lumen's co-founder and CEO. "Mark shares our mission-oriented perspective and deep respect for high-quality corporate governance, and we're excited to welcome his independent voice to the Lumen boardroom."

    "Lumen Bioscience is pioneering novel drug discovery and production technologies that have the potential to broadly impact many devastating diseases," said Dr. Litton. "I look forward to working with the team as they continue to advance their unique drug development platform."

    At Athira, Dr. Litton has helped direct the company's Series B and initial public offering. During his tenure at Alder, he led the company's business operations and played a key role in the company's IPO, follow-on financings, collaborations, and partnerships. Prior to Alder, Dr. Litton held executive leadership roles at Celltech Group, Chiroscience Group plc, and Ribozyme. Dr. Litton holds a PhD in Immunology from Stockholm University, an MBA from Santa Clara University, and a BS in Biochemistry from the University of California, Santa Cruz.

    About Lumen

    Lumen Bioscience discovers, develops, and manufactures biologic drugs for several prevalent, worldwide diseases—many of which currently lack any effective treatments. The company's unique drug development and manufacturing platform offers the potential to transform the biologics industry through increased speed, mass-market scale, and exponentially lower costs than current approaches. Lumen's clinical pipeline includes investigational biologic drugs for C. difficile infection, Covid-19, norovirus, and traveler's diarrhea. For more information, visit: www.lumen.bio.

    Media Contact:

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/lumen-bioscience-announces-appointment-of-dr-mark-litton-to-board-of-directors-301148413.html

    SOURCE Lumen Bioscience

    View Full Article Hide Full Article
  5. -Study to evaluate the safety and efficacy of ATH-1017 to improve mild-to-moderate Alzheimer's disease-

    SEATTLE, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in the company's Phase 2/3 clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer's disease. The clinical trial, known as LIFT-AD (www.lift-adtrial.com), will enroll up to approximately 300 Alzheimer's patients in the United States and Australia.

    "Data from our previous study show functional biomarker effects indicating…

    -Study to evaluate the safety and efficacy of ATH-1017 to improve mild-to-moderate Alzheimer's disease-

    SEATTLE, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in the company's Phase 2/3 clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer's disease. The clinical trial, known as LIFT-AD (www.lift-adtrial.com), will enroll up to approximately 300 Alzheimer's patients in the United States and Australia.

    "Data from our previous study show functional biomarker effects indicating potentially positive effects of ATH-1017 on brain function in Alzheimer's patients," said Hans Moebius, M.D., Ph.D., Chief Medical Officer at Athira. "Our goal is to confirm these compelling effects in a larger ATH-1017 study as there is a significant unmet need for new Alzheimer's treatments."

    The Phase 2/3 clinical trial (clinicaltrials.gov identifier NCT04488419) is a randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of ATH-1017 in individuals with mild-to-moderate Alzheimer's disease. Clinical efficacy will be measured by improvement in cognition and global/functional assessments comparing treatment arms to placebo. Up to approximately 300 patients will be randomized across two dose groups and one placebo group on a 1:1:1 basis to receive a daily subcutaneous injection of ATH-1017 or placebo over a treatment course of 26 weeks.

    "Embarking on this trial to evaluate our new approach to treating Alzheimer's is the start of a collective experience that will involve not only individuals with Alzheimer's but their caregivers and family members," said Leen Kawas, Ph.D., President and Chief Executive Officer at Athira. "We appreciate the collaborative efforts that are underway to evaluate the potential of ATH-1017 to improve mild-to-moderate Alzheimer's disease."

    Athira's completed Phase 1a/b clinical trials of ATH-1017 for the treatment of Alzheimer's disease established that the treatment was generally well tolerated at all tested doses. Measures evaluating brain function with electroencephalogram (qEEG) also produced a strong suite of translational data. Additionally, a statistically significant improvement in Event-Related Potential (ERP) P300 latency, a functional measure of working memory processing speed and executive function, was noted in patients with Alzheimer's disease following multiple dose treatment with ATH-1017 compared with those receiving placebo. Through the LIFT-AD clinical trial and other anticipated clinical trials, Athira is seeking to establish a connection between these P300 latency results and improved cognition.

    ATH-1017's novel mechanism of action is agnostic to the underlying disease pathology of Alzheimer's and other dementias. It focuses on network recovery and information transmission in the brain, which has the potential to improve clinical outcomes for patients.

    About ATH-1017

    ATH-1017 is a small molecule therapeutic specifically designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor, MET, which are expressed in normal central nervous system function, in order to impact neurodegeneration and regenerate brain tissue. In addition to Alzheimer's disease, ATH-1017 is designed to address the broader dementia population, including Parkinson's disease dementia.

    About Athira Pharma, Inc.

    Athira, headquartered in Seattle, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer's and Parkinson's dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

    Forward-Looking Statements

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding ATH-1017 as a potential treatment for Alzheimer's and other dementias; Athira's platform technology and potential therapies; future development plans; clinical and regulatory objectives and the timing thereof; anticipated design of planned clinical trials; expectations regarding the potential efficacy and commercial potential of Athira's product candidates, including ATH-1017; the anticipated presentation of data; the results of Athira's research and development efforts and Athira's ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "pursue," and other similar expressions among others. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the preliminary data for Athira's ATH-1017 product candidate from the Phase 1a/b trials will not continue or persist; cessation or delay of any of the ongoing clinical trials and/or Athira's development of ATH-1017 may occur; future potential regulatory milestones of ATH-1017, including those related to current and planned clinical studies may be insufficient to support regulatory submissions or approval; the impact of the COVID-19 pandemic on Athira's business; Athira's research and development efforts and its ability to advance product candidates into later stages of development may fail; any one or more of Athira's product candidates may not be successfully developed, approved or commercialized; adverse conditions in the general domestic and global economic markets; as well as the other risks detailed in Athira's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

    Investor & Media Contact:

    Julie Rathbun

    Athira Pharma



    206-769-9219

    Primary Logo

    View Full Article Hide Full Article
View All Athira Pharma Inc. News